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Abstract
During pregnancy, physiologic hormonal changes provoke a significant increase in triglyceride levels. Genetic 
abnormalities of triglyceride metabolism and secondary factors may multiply the risk of severe lipid abnormalities. 
Although severe gestational hypertriglyceridemia can be a life-threatening condition for both mother and fetus, its 
optimal treatment has not been fully clarified. A 33-year-old woman at 37 weeks of her second pregnancy was admitted 
to our clinic. Her triglyceride level was 57.8 mmol/L. Abdominal pain, nausea, vomiting or any other complaints were 
not reported. She kept a fat-restricted diet, however her triglyceride level remained 41 mmol/L. Therefore we decided to 
perform plasmapheresis with a replacement of human albumin as a colloidal solution. Complications did not occur during 
the treatment. Plasmapheresis reduced her triglyceride level by 54.1% (to 18.8 mmol/L), and the patient delivered a 
healthy female neonate at 40 weeks. In case of significantly increased values, plasmapheresis is a fast, effective and safe 
method for decreasing triglyceride level even in the third trimester.
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INTRODUCTION
Maternal lipids are extremely important for developing a fetus. While cholesterol is a crucial molecule 
in placental steroid synthesis, fatty acids participate in placental oxidation processes and membrane 
development[1]. In pregnant women, significant alterations in lipid levels are in connection with estrogen, 
progesterone and human placental lactogen synthesis[2]. During normal pregnancy, increased lipolytic 
activity raises the release of free fatty acid and the production of very low-density lipoprotein (VLDL). 
Besides, the elimination of VLDL is decreased due to the reduced activity of lipoprotein lipase in fatty 
tissue[3]. Eventually, there is a 2-4 fold increase in triglyceride level by third trimester[4].
Genetic abnormalities of triglyceride metabolism can provoke severe hypertriglyceridemia in pregnancy. 
In familial combined hyperlipidemia and familial hypertriglyceridemia, we see an increased formation of 
triglyceride-rich lipoproteins (chylomicrons and VLDLs). Ineffective lipolysis of these particles can cause 
familial chylomicronemia due to the mutations in lipoprotein lipase, apolipoprotein CII or apolipoprotein 
AV[5]. In familial dysbetalipoproteinemia, apolipoprotein E2/E2 genotype reduces hepatic clearance of 
chylomicron remnants[5]. In addition, secondary factors such as poorly controlled diabetes mellitus (via 
decreasing the activity of lipoprotein lipase), hypothyroidism, nephrotic syndrome and some medications 
(glucocorticoids) may aggravate gestational hypertriglyceridemia[6].
Hypertriglyceridemia during pregnancy increases the risk of acute pancreatitis (especially if triglyceride level 
is above 11.4 mmol/L), hyperviscosity syndrome and pre-eclampsia in mother, macrosomia, premature birth 
or fetal death in fetus[6-9]. 
At first, treatment of the underlying disease and fat-restricted diet are recommended[6]. During pregnancy, 
lipid-lowering medications (fibrate, nicotinic acid, statin, and ezetimibe) should be stopped due to their 
possible teratogenic effects[10]. Novel lipid-lowering agents including microsomal transfer protein and 
proprotein convertase subtilisin/kexin type 9 inhibitors are also contraindicated. Therefore, in the case of 
non-responding severe hypertriglyceridemia plasmapheresis should be considered. This is an extracorporeal 
procedure, when plasma is separated from the blood and processed to eliminate selective components 
including triglyceride-rich lipoprotein particles. The treated plasma is then reinfused although, on occasion, 
it is completely eliminated and replaced by an isovolumetric solution. Most of the studies use plasmapheresis 
as a treatment of hypertriglyceridemia associated pancreatitis. In some cases, they perform plasmapheresis to 
prevent pancreatitis. It must be noted that the timing and frequency of plasmapheresis procedures were not 
uniform in these studies[11-13]. During plasmapheresis serum triglyceride level can be decreased by 66%-70%[12,13]. 
CASE REPORT
A 33-year-old woman at 37 weeks of her second pregnancy was admitted to our clinic. Her gynecologist 
indicated routine laboratory examinations, which remained unsuccessful because of lipemic blood sample. 
Therefore, we checked her triglyceride level and found that it was significantly elevated (57.8 mmol/L). Abdominal 
pain, nausea, vomiting or any other complaints were not reported. Based on physical examination, there were 
no eruptive xanthomas, palmar crease xanthomas or lipaemia retinalis. Her body mass index was within the 
normal range before pregnancy (53 kg), and her total body weight gain was 9 kg during pregnancy. In her 
history, there was no diabetes mellitus or any other secondary causes of hypertriglyceridemia. The diagnosis 
of gestational diabetes mellitus was evaluated according to the Hungarian national recommendation. 
We used the modified 1999 WHO recommendation (gestational diabetes mellitus: 75 g CH oral glucose 
tolerance test (OGTT) at 24-28 gestation weeks: fasting plasma glucose ≥ 6.1 mmol/L, 120 min plasma glucose ≥ 
7.8 mmol/L)[14]. Based on the fasting plasma glucose (5.2 mmol/L) and the OGTT (plasma glucose: 120 min: 
7.1 mmol/L) the diagnosis of gestational diabetes mellitus was excluded. In her family history, her mother 
and grandmother had mixed hyperlipidemia. Her first pregnancy had terminated without any complication 
however, lipid parameter measurement was not performed. Before her pregnancy, she had not taken any 
lipid-lowering medications. She had not followed a fat-restricted diet during her pregnancy. Table 1 shows 
the laboratory parameters before treatment. Markedly elevated triglyceride and total cholesterol levels were 
detected. Apolipoprotein B100 and lipoprotein (a) levels were also above the upper border of the normal 
range. Based on the result of lipid electrophoresis, a significant increase in the level of VLDL may cause 
hypertriglyceridemia. 
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Her levels of lipase, amylase, transaminases, and inflammatory markers were in the normal range. Abdominal 
ultrasound showed neither cholelithiasis nor any symptoms of pancreatitis. The development of fetus was 
appropriate. The patient case was followed by obstetrician, endocrinologist, neonatologist, and dietitian.
She started on a fat-restricted diet (< 20% of total calories from fat daily) and consumed 15 g medium-chain 
triglycerides and 3 g omega-3-fatty esters daily, but two days later her triglyceride level remained 41 mmol/L. 
Therefore, she was immediately admitted to our ICU and we decided to perform plasmapheresis using 
central veins with human albumin infusion as a colloidal solution with one plasma volume exchange and 
FRESENIUS Com.tec Kabi Therapeutic Plasma Exchange machine. 
There were not any complications during plasmapheresis. The patient delivered a healthy female neonate 
weighing 3,150 g at 40 weeks. One day after delivery her triglyceride level was decreased to 15.68 mmol/L, 
two more days later it was 7.3 mmol/L without any further plasmapheresis procedures. The alterations of 
lipid parameters are shown in Figures 1 and 2.
During lactation, we suggested fat-restricted diet and regular control of triglyceride level. Gene 
polymorphisms of lipoprotein lipase and Apolipoprotein E were determined. The patient has ApoE 3/3 
genotype, therefore, we could exclude the familial dysbetalipoproteinemia as a possible cause. The patient is 
wild type for two common polymorphisms of LPL (LPL-D9N and LPL-N291S) causing hypertriglyceridemia. 
Although, there was some chylomicron increment, a significant increase in the level of VLDL determined by 
lipid electrophoresis excludes the possibility of severe LPL deficiency.    
DISCUSSION
In the last decades, women had increasing access to graduation in professional schools, building careers, 
and using contraceptive methods worldwide[15]. This has led to the delay of first marriage and first child 
birth. In fact, the average age at first birth rose from 22.7 years in 1980 to 28.2 years in 2013[16]. Indeed, many 
women are choosing to delay attempts to conceive to their thirties and forties, when they have a significantly 
higher risk of type 2 diabetes, metabolic syndrome and other non-communicable diseases causing lipid 
abnormalities. Furthermore, the proportion of women of reproductive age who are overweight or obese is 
also increasing at an alarming rate[17]. The incidence of severe hypertriglyceridemia in pregnant women 
might be higher than we believe.
Although during pregnancy measurement of lipid parameters is not performed routinely, in case of a 
lipemic blood sample, suggestive patient history or previous pancreatitis, determination of triglyceride level 
is definitely required. 
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Table 1. Laboratory parameters before treatment
Parameter Unit Value Reference range
Total cholesterol mmol/L 24.7 (H) < 5.2
Triglyceride mmol/L 41.00 (H) < 1.7
Apolipoprotein A g/L 1.86 > 1.15
Apolipoprotein B100 g/L 2.25 (H) < 1
Lipoprotein(a) mg/L 114 (H) < 30
sTSH mU/L 0.978 0.300-4.200
fT3 pmol/L 1.8 (L) 2.4-6.3
fT4 pmol/L 8.2 (L) 12.0-22.0
CRP mg/L 8.2 (H) < 5.2
Lipid electrophoresis
   AlfaLP % 7 (L) 15-40
   PreßLP % 53 (H) 2-31
   BetaLP % 34 (L) 42-70
   Chylomicron % 6 -
While treatment of gestational hypertriglyceridemia-induced pancreatitis with plasmapheresis is well-
defined[6], the timing and frequency of plasmapheresis procedures in gestational hypertriglyceridemia 
without pancreatitis should be determined individually, depending on patient’s history, symptoms, duration 
of pregnancy and the lowest triglyceride level available with diet. To date, there is no available guideline for 
the management of severe hypertriglyceridemia that develops during pregnancy. Although some case reports 
and series were published[12], including treatment methods such as intravenous insulin and glucose, heparin 
and apheresis, they are not comparable, therefore, the clinician has to come to the optimal decision. The 
timing of the extracorporeal treatment can be an especially tender spot, since all of these procedures may 
provoke adverse events such as hemodynamical instability, which can be especially critical in late pregnancy. 
Early plasmapheresis as a successful treatment in hypertriglyceridemia-induced acute pancreatitis in first-
trimester pregnancy following in vitro fertilization was reported previously[18]. Here, we present a successful 
treatment in late pregnancy without adverse events. 
Figure 1. Lipid parameters before and immediately after treatment plasmapheresis, and one day after delivery
Figure 2. Changes (%) in lipid parameters before and immediately after plasmapheresis treatment
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Regular check-up is highly recommended after delivery, during lactation and especially during subsequent 
pregnancies. Close cooperation between endocrinologist or lipid specialist and gynaecologist is also 
necessary. With the exception of lipoprotein lipase deficiency, primary hypertriglyceridemia disorders 
usually present in adulthood. Indeed, dozens of causative genetic abnormalities were described in severe 
hypertriglyceridemia. Genetic testing is available for suspected cases of familial chylomicronemia syndrome 
and dysbetalipo-proteinemia, but is not necessary for treatment[5]. Still, sequencing of candidate genes may 
help to guide future individualized therapeutic strategies in order to prevent further complications and to 
identify affected relatives using cascade screening.
In case of significantly increased values, plasmapheresis is a fast, effective and safe method for decreasing 
triglyceride level even in late pregnancy. However, multicentre, prospective studies including a larger 
number of participants are required to support the observations and to define novel therapeutic guidelines. 
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